 |
 |

Study Probes Best Choice of Drug to Reduce Phosphate in Patients on Dialysis
Mike Mitka
JAMA. 2007;298(17):1995-1996.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
A costly and widely used medication for patients on hemodialysis is no better at reducing mortality than lower-cost alternatives, according to the findings of a new study.
In the largest prospective randomized study to date comparing patients on hemodialysis who were given sevelamer hydrochloride (Renagel, Genzyme Corporation, Cambridge, Mass) or a calcium-based binder to treat hyperphosphatemia, the Dialysis Clinical Outcomes Revisited (DCOR) trial, researchers found that all-cause mortality was the same in the group taking sevelamer (267 deaths) and the group taking a calcium-based binder (275 deaths) (Suki WN et al. Kidney Int. doi:10.1038/sj.ki.5002466 [published online ahead of print August 29, 2007]).
| |
Maintaining appropriate levels of phosphate is important for patients on hemodialysis, but the best way to do so remains open to debate. (Photo credit: AJPhoto/www.sciencesource.com)
|
|
However, in a prespecified secondary analysis of the trial (which was sponsored by Genzyme), the researchers did find . . . [Full Text of this Article] GETTING RID OF PHOSPHATE
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Phosphorus Binders and Survival on Hemodialysis
Isakova et al.
J. Am. Soc. Nephrol. 2009;20:388-396.
ABSTRACT
| FULL TEXT
|